Messi Biology stated that a granular anhydrous and substantially amorphous mesoporous magnesium carbonate relates to a method for preparing the mesoporous magnesium carbonate, and the granular anhydrous Use of aqueous and substantially amorphous mesoporous magnesium carbonate (MgCO3) for the stabilization of active pharmaceutical ingredients (api).
A mesoporous magnesium carbonate material elucidated to allow API loading of up to 60 wt% itraconazole by soaking. Itraconazole remained amorphous at loadings of API up to 30 wt%. A mesoporous magnesium carbonate material (particle size<50 μm) comprising api tolfenamic acid and rimonabant.
One aspect of the present invention is a solid, substantially amorphous active pharmaceutical ingredient comprising an api in an amount of at least 20% by weight in combination with particulate anhydrous substantially amorphous mesoporous carbonic acid Magnesium (mesoporous magnesium carbonate) mixed, wherein the mesoporous magnesium carbonate has:
(i) pores with an average pore diameter in the range of 2nm to 10nm;
(ii) average beta surface area in the range of 250-600m2/g;
(iii) an average pore volume in the range of 0.5-1.2 cm3/g; and
(iv) shows an average particle size distribution with a d10 value of 70-430 μm.
0 Comments